„Research for a life without cancer“ is our mission at the German Cancer Research Center. We investigate how cancer develops, identify cancer risk factors and look for new cancer prevention strategies. We develop new methods with which tumors can be diagnosed more precisely and cancer patients can be treated more successfully. Every contribution counts – whether in research, administration or infrastructure. This is what makes our daily work so meaningful and exciting.
Together with selected university partner sites, the DKFZ has established the German Cancer Consortium (DKTK). The alliance between the DKFZ as the core center and the university partner sites in Berlin, Dresden, Essen/Düsseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich and Tübingen establishes joint translation centers at the University Medical Centers of each of the partner sites.
The DKTK contributes significantly to filling the translational gap between basic and clinical cancer research, thereby developing new strategies for personalized oncology in prevention, diagnosis and treatment of cancer. DKTK conducts transformative translational cancer research, educates the next generation of translation-oriented medical and clinical scientists and establishes strong pipelines towards clinical cancer research and the economy. Further information can be found at www.dktk.org .
The German Cancer Research Center (DKFZ) is seeking for the DKTK partner site Munich from May 2025 a Junior Group Leader in “Cancer Systems Biology”.
Reference number: 2025-0010
Under the leadership of Prof. Martin Sos, head of the Division of Translational Oncology at the DKTK partner site Munich, we are seeking to appoint a junior group leader to expand our efforts in the field of functional and computational cancer biology. The scientific interest should match with the profile of the DKTK partner site Munich and the Ludwig-Maximilians-University Munich (LMU Munich) with a focus on lung cancer and the evolution of drug resistance to support and further develop the translational cancer research portfolio.
The DKTK partner site Munich and the DKFZ provide access to first-class, state-of-the-art core facilities in Munich and Heidelberg. Translational research activities are supported by access to large patient cohorts, high quality tumor tissue banks and excellent clinical research facilities. The junior group leader will be employed at the DKFZ in Heidelberg, whereas the junior group will be physically located in Munich, embedded in the Division of Translational Oncology (headed by Prof. Martin Sos; DKTK/LMU; Max-Lebsche-Platz, Munich).
Original Stellenanzeige mit Gehaltsinformation auf StepStone.de